This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

OrthoAccelA® Technologies, Inc. Launches Investigator Initiated Research Program With Announcement Of Four Inaugural Grant Recipients

HOUSTON, Dec. 11, 2013 /PRNewswire/ -- OrthoAccel® Technologies, Inc. launches its Investigator Initiated Research Program by awarding initial grants to four academic research institutions. With patient demand steadily trending towards faster orthodontic treatment, OrthoAccel developed the grant program to generate more evidence-based research about accelerated orthodontics.

OrthoAccel manufactures AcceleDent® Aura, the only FDA-cleared, Class II medical device that has been proven to accelerate orthodontic treatment up to 50 percent.

"We originally went to market with AcceleDent because we knew consumers wanted faster orthodontic treatments," said Mike Lowe, president and CEO of OrthoAccel.  "With that trend continuing, OrthoAccel's Investigator Initiated Research Program will support academic researchers as they discover new uses for AcceleDent while also expanding clinical knowledge about accelerated orthodontics through applied biomedical research."

OrthoAccel awarded the inaugural four grants to the following universities, which are listed with the proposed study title:
  • Marquette University "Effect of mechanical vibration on orthodontic tooth movement ex vivo"
  • University of Alabama at Birmingham "An investigation of time usage during orthodontic treatment"
  • University of Colorado "Vibratory stimulation therapy for pain reduction after orthodontic archwire insertion"
  • University of Connecticut "Biomarkers of orthodontic tooth movement with fixed appliances and vibration appliance therapy – a randomized clinical trial"

Each grant application was reviewed and evaluated based on, but not limited to, its alignment to OrthoAccel's corporate strategy, investigator's credentials and proposal quality. Zaffer Syed, OrthoAccel's director of clinical and regulatory affairs, led the review team.

"We're very impressed with the initial round of research proposals and look forward to making this an annual program," said Syed. "Just as AcceleDent is a novel orthodontic innovation that's now offered in over 1,000 locations in the United States and Canada, OrthoAccel's Investigator Initiated Research Program strives to foster even more innovation and drive enhanced improvements to orthodontic treatment and overall oral care.

Syed added that independent research is important to advancing knowledge about OrthoAccel's products and treatments and that the entire orthodontic industry can potentially benefit from these funded studies.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.70 0.00%
FB $101.91 0.00%
GOOG $683.11 0.00%
TSLA $150.47 0.00%
YHOO $26.76 0.00%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs